MBCCOP - Medical College of Georgia Cancer Center

Summary

MBCCOP - Medical College of Georgia Cancer Center is a medical facility located in Augusta, Georgia. This center is recognized for care of Solid Tumors, Breast Cancer, Leukemia, Cancer, Acute Myeloid Leukemia and other specialties. MBCCOP - Medical College of Georgia Cancer Center is involved with conducting 103 clinical trials across 243 conditions. There are 9 research doctors associated with this hospital, such as Sharad Ghamande, Jorge Cortes, MD, Vamsi Kota, MD, and Locke J. Bryan.

Top PIs

Clinical Trials running at MBCCOP - Medical College of Georgia Cancer Center

Acute Myeloid Leukemia

Ovarian Cancer

Cancer

Cervical Cancer

Non-Hodgkin's Lymphoma

Leukemia

Multiple Myeloma

Chronic Myeloid Leukemia

Endometrial Cancer

Lung Cancer

DFP-10917

for Acute Myeloid Leukemia

Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.

Recruiting

2 awards

Phase 3

4 criteria

Ziftomenib Combinations

for Acute Myeloid Leukemia

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.

Recruiting

1 award

Phase 1

Ziftomenib Combinations

for Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Recruiting

1 award

Phase 1

9 criteria